Singapore, March 2nd, 2023 – Update on Detection of the Influenza A subtypes.
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of Influenza A H3N2, H1N1, H5N1, and H7N9 subtypes listed in GISAID, NCBI, and BV-BRC up until 31st January 2023.
Our analysis has confirmed that our assays maintain their stated level of performance.
*The Influenza A virus detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ Flu/RSV Assay (PCRAE0106)
． VitaPCR™ Flu A&B Assay (PCRAE0103)
For more information, contact us at service@credodxbiomed.com.
